A Cross-Sectional Study to Assess HPV Knowledge and HPV Vaccine Acceptability in Mali

Despite a high prevalence of oncogenic human papilloma virus (HPV) infection and cervical cancer mortality, HPV vaccination is not currently available in Mali. Knowledge of HPV and cervical cancer in Mali, and thereby vaccine readiness, may be limited. Research staff visited homes in a radial pattern from a central location to recruit adolescent females and males aged 12–17 years and men and women aged ≥18 years (N = 51) in a peri-urban village of Bamako, Mali. Participants took part in structured interviews assessing knowledge, attitudes, and practices related to HPV, cervical cancer, and HPV vaccination. We found low levels of HPV and cervical cancer knowledge. While only 2.0% of respondents knew that HPV is a sexually transmitted infection (STI), 100% said they would be willing to receive HPV vaccination and would like the HPV vaccine to be available in Mali. Moreover, 74.5% said they would vaccinate their child(ren) against HPV. Men were found to have significantly greater autonomy in the decision to vaccinate themselves than women and adolescents (p = 0.005), a potential barrier to be addressed by immunization campaigns. HPV vaccination would be highly acceptable if the vaccine became widely available in Bamako, Mali. This study demonstrates the need for a significant investment in health education if truly informed consent is to be obtained for HPV vaccination. Potential HPV vaccination campaigns should provide more information about HPV and the vaccine. Barriers to vaccination, including the significantly lower ability of the majority of the target population to autonomously decide to get vaccinated, must also be addressed in future HPV vaccine campaigns

Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali.

Although screening for pre-cancerous cervical lesions and human papilloma virus (HPV) vaccination are accepted and effective means to prevent cervical cancer, women in Mali have limited access to these interventions. In addition, cervical cancer prevention by HPV vaccination has been controversial in some settings. To reduce cervical cancer prevalence and increase HPV vaccine uptake, it is important to understand the level of knowledge about cervical cancer screening and practices related to vaccination in at-risk populations. In this study, the level of knowledge about HPV and cervical cancer and attitudes towards vaccination were assessed among 301 participants (male and female, adults and adolescents) in a house-to-house survey in two urban neighborhoods in Bamako, Mali. The survey was combined with a brief educational session on HPV. Prior to the education session, overall knowledge of HPV infection and cervical cancer was very low: only 8% knew that HPV is a sexually transmitted infection (STI). Less than 20% of women had ever consulted a gynecologist and less than 3% had ever had cervical cancer screening. After hearing a description of HPV vaccine, more than 80% would accept HPV vaccination; fathers and husbands were identified as primary decisions makers and local clinics or the home as preferred sites for vaccination. This study provides information on STI knowledge and vaccine acceptance in Bamako, Mali in 2012, prior to the introduction of HPV vaccination

Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali.

BACKGROUND:Cervical cancer is one of the most common and lethal cancers in West Africa. Even though vaccines that protect against the most common Human papillomavirus (HPV) strains, 16 and 18, are currently in use in developed countries, the implementation of these vaccines in developing countries has been painfully slow, considering the pre-eminence of HPV-associated cervical cancer among women in those countries. AIM:We performed serological and PCR-based assessment of blood and tissue specimens obtained from women undergoing cervical cancer-related surgery at a major urban hospital in Bamako. Since several therapeutic HPV vaccines are currently in clinical trials, we also assessed willingness to participate in HPV cancer vaccine trials. METHODS:Blood and biopsy samples of 240 women were evaluated for HPV types 16 and 18 by serology and PCR. Knowledge regarding the HPV vaccine and autonomy to decide to vaccinate their own child was assessed with a standardized questionnaire. RESULTS:HPV 16 and 18 were identified in 137/166 (82.5%) cervical cancer biopsy samples by PCR. Co-infection with both HPV 16 and 18 was significantly more frequent in women over 50 years of age than in younger women (63.0% vs. 37.0%). 44% of study participants said they would be willing to vaccinate their child with HPV vaccine. Only 39% of women participating in this study reported that they would be able to make an autonomous decision to receive HPV vaccination. Permission from a male spouse or head of household was identified as important for participation by 59% of the women. CONCLUSION:This study provides strong support for the introduction of currently available HPV vaccines in Mali, and also provides key information about conditions for obtaining informed consent for HPV vaccine trials and HPV vaccination in Mali

Gynecological care knowledge and practices (female participants).

<p>Gynecological care knowledge and practices (female participants).</p

Characteristics of the study participants.

<p>Characteristics of the study participants.</p

Attitudes about HPV vaccination and decision-making.

<p>Attitudes about HPV vaccination and decision-making.</p

Knowledge about CC screening.

<p>Female participants (N = 149) were asked if they knew what CC screening was and about access to CC screening in Mali. Results are presented before and after the educational session for all female participants (Total, N = 149), female adults (Women, N = 75) and female adolescents (Girls, N = 74). * p<0.01 and ** p<0.05 when compare to answers before the educational session (McNemar test).</p

Knowledge of STIs, HPV, and CC.

<p>Participants were asked about STIs (A), HPV (B) and cervical cancer (C) before and after a brief educational session. Percentages of participants able to answer the question are reported in the graphs for all participants (Total, N = 301), female (N = 148), male (N = 152) and adolescents (N = 146). * p<0.01 when compared to answers before the educational session (McNemar test). Women reported much more extensive knowledge of STIs than HPV, and while a brief educational session improved knowledge, more needs to be done.</p

Prevalence of HPV 16 and 18 in women with cervical cancer.

<p><b>A</b>. Percentage of positive samples for HPV 16 and 18 by PCR (n = 166). Untyped samples were negative for both HPV 16 and 18. <b>B</b>. Percentage of positive samples for HPV 16 only, HPV 18 only (mono-infection) or both HPV 16 and 18 (co-infection) by PCR (n = 135). <b>C</b>. Repartition into age groups of positive samples for HPV 16 or HPV 18 (mono-infection) or for both (co-infection) by PCR. For mono- and co-infections, lighter shades represent the percentage of infected women within the co- or mono-infected group aged 49 years or younger; darker shades represent the percentage of infected women aged 50 years or older.</p

Detection of HPV16/18 neutralizing antibodies.

<p>Presence of antibodies to HPV types 16 and 18 by a VLP-based competitive Luminex immunoassay (cLIA). Results are presented as percentage of total number of available blood samples (N = 160).</p